BRII-B(02137),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02137 BRII-B

Closed 08-24 16:08:19

1.010

-0.005

-0.49%

High1.050	Low0.970	Vol1.69M
Open1.000	D1 Closing1.015	Amplitude7.88%
Mkt Cap729.22M	Tradable Cap729.22M	Total Shares722.00M
T/O1.67M	T/O Rate0.23%	Tradable Shares722.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02137","market":"HK","secType":"STK","nameCN":"BRII-B","latestPrice":1.01,"timestamp":1787558899243,"preClose":1.015,"halted":0,"volume":1688500,"delay":0,"changeRate":-0.0049261083743841316,"floatShares":722000000,"shares":722000000,"eps":-0.308397,"marketStatus":"Closed","change":-0.005,"latestTime":"08-24 16:08:19","open":1,"high":1.05,"low":0.97,"amount":1666022,"amplitude":0.078818,"askPrice":1.01,"askSize":500,"bidPrice":0.975,"bidSize":10000,"shortable":0,"etf":0,"ttmEps":-0.279,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787621400000},"marketStatusCode":5,"adr":0,"listingDate":1626105600000,"exchange":"SEHK","adjPreClose":1.015,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":1.855698,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02137/tweets","defaultTab":"tweets","newsList":[{"id":"2661241804","title":"Sinopharm Interim Revenue Edges Down on Softness in Pharmaceutical Distribution Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241804","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661241804?lang=en_us&edition=fundamental","pubTime":"2026-08-24 08:02","pubTimestamp":1787529767,"startTime":"0","endTime":"0","summary":"Sinopharm interim revenue edges down on softness in pharmaceutical distribution businessOverviewChina pharmaceutical distributor's interim revenue declined slightly year-on-yearNet income attributable","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44K04V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4204","02137","BK1230","BK1587","BK1197","LU0640798160.USD","LU1115378108.SGD","HK0000306701.USD","HK0000320264.USD","BK1515","EDMCQ","BK1500","02696","HK0000320223.HKD","HK0000306685.HKD","BK1161","01099","HK0000165453.HKD","00656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661901362","title":"Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661901362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661901362?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:15","pubTimestamp":1787346928,"startTime":"0","endTime":"0","summary":"Niki BioSolutionsweighs financing options as going-concern warning clouds post-merger outlookOverviewUS biopharmaceutical developer's H1 net loss widened, with loss per share at $1.6Operating expenses","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1583","BK1521","BK1589","IE00BZ08YS42.EUR","BK1587","IE00BZ08YT58.USD","BK1191","BK4139","NIKI","02137","BK1161","06996","01177","IE00BZ08YR35.GBP","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264711","title":"Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264711","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661264711?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:38","pubTimestamp":1787308735,"startTime":"0","endTime":"0","summary":"Biotech firm Antengene's H1 revenue jumps on licensing dealsOverviewBiotech company's H1 revenue rose sharply on licensing deals with UCB, K2 TherapeuticsCompany swung to H1 net profit from loss a yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1574","BK1587","02137","06996","BK1161","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179632017","title":"Hong Kong Stock Market Flash: BRII-B Surges Over 8% as Interim Loss Narrows 32.08% and Promising Clinical Data Emerges","url":"https://stock-news.laohu8.com/highlight/detail?id=1179632017","media":"Stock News","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179632017?lang=en_us&edition=fundamental","pubTime":"2026-08-21 11:41","pubTimestamp":1787283672,"startTime":"0","endTime":"0","summary":"Shares of BRII-B (02137) climbed more than 8% before the midday break, trading up 8.16% at HK$1.06 with turnover reaching HK$52.37 million.The company released its interim results for the six months...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","KCAI","BK1587","VXUS","BK1161","BK4588","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661125866","title":"China's Brii Biosciences Interim Net Loss Narrows on Lower R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661125866","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661125866?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:14","pubTimestamp":1787267641,"startTime":"0","endTime":"0","summary":"China's Brii Biosciences interim net loss narrows on lower R&D expensesOverviewChina biotech firm's interim net loss narrowed for six months ended June 30, 2026Lower R&D and administrative expenses co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL1N44H13O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06855","BK1161","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661638258","title":"Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2661638258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661638258?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:10","pubTimestamp":1787267400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABLCVSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1587","02137","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661325830","title":"Brii Biosciences: Hy Other Income Rmb19.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2661325830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661325830?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:02","pubTimestamp":1787266922,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nPLXMQ7KNH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1574","02137","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661258376","title":"Brii Bio H1 FY26 Loss Narrows 32.1% to RMB 101 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661258376","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661258376?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:01","pubTimestamp":1787266863,"startTime":"0","endTime":"0","summary":"Brii Bio H1 FY26 loss narrows 32.1% to RMB 101 millionBrii Bio posted an IFRS net loss of RMB 101 million, narrowing 32.1% from a year earlier; basic loss per share improved to RMB 0.14.Other income f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4prdW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","BK1161","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161721104","title":"Brii Biosciences Sets 20 August 2026 Board Meeting to Review 1H26 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1161721104","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161721104?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:44","pubTimestamp":1786113898,"startTime":"0","endTime":"0","summary":"On 7 August 2026, Brii Biosciences Limited announced that its board of directors will convene on Thursday, 20 August 2026. The agenda includes consideration and approval of the unaudited interim...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657449946","title":"Brii Biosciences Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657449946","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657449946?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:28","pubTimestamp":1786112893,"startTime":"0","endTime":"0","summary":"Brii Biosciences schedules board meeting to review interim resultsBrii Biosciences scheduled a board meeting for Aug. 20, 2026 to review unaudited interim results for the six months ended June 30, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL6M3pwP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","02137","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121418980","title":"Analyzing the First Half Fiscal Revenue and Expenditure Growth Rates in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1121418980","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121418980?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:41","pubTimestamp":1785292872,"startTime":"0","endTime":"0","summary":"Zhu Qing, a chief professor at the Institute of Fiscal and Public Policy at Renmin University of China, explains that the full-caliber fiscal budget consists of four main components, known as the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1161","02137","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182017426","title":"Brii Biosciences (BRII-B) Adds 46.56 Thousand New Shares in June; Confirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1182017426","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182017426?lang=en_us&edition=fundamental","pubTime":"2026-07-07 17:25","pubTimestamp":1783416359,"startTime":"0","endTime":"0","summary":"Brii Biosciences Limited filed its Monthly Return for Equity Issuer to the Hong Kong Stock Exchange on 7 July 2026, detailing share-capital movements for June 2026. Authorised capital unchanged   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648957006","title":"Is Brii Biosciences (HKG:2137) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648957006","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648957006?lang=en_us&edition=fundamental","pubTime":"2026-07-04 09:10","pubTimestamp":1783127413,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2137/brii-biosciences-shares/news/is-brii-biosciences-hkg2137-in-a-good-position-to-deliver-on","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2137/brii-biosciences-shares/news/is-brii-biosciences-hkg2137-in-a-good-position-to-deliver-on","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1587","BK1161","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648631520","title":"Brii Bio Announces Topline End-of-treatment Data from Phase 2B Enrich and Enhance Studies for the Treatment of Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2648631520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648631520?lang=en_us&edition=fundamental","pubTime":"2026-07-03 08:00","pubTimestamp":1783036802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nTUA7LQXCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02137","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198589578","title":"BRII-B Reports End-of-Treatment Topline Data from Phase 2b ENRICH and ENHANCE Studies for Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=1198589578","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198589578?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:06","pubTimestamp":1783033618,"startTime":"0","endTime":"0","summary":"Clinical trial results from two Phase 2b studies have been released.The ongoing Phase 2b ENRICH and ENHANCE studies have concluded their treatment phase, with top-line results now available.These...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02137","BK1574","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648763994","title":"Brii Biosciences Says Arbitration with Vir Clouds Future of Elebsiran Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648763994","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648763994?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:56","pubTimestamp":1783033010,"startTime":"0","endTime":"0","summary":"Brii Biosciences says arbitration with Vir clouds future of elebsiran programBrii flagged ongoing arbitration with Vir Biotechnology that has made the future of its elebsiran hepatitis B program uncer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL1dwW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK1574","02137","BK1161","BK1587","VIR","BK4535","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646035396","title":"Wuxi XDC Appoints Yuan Fang Joint Company Secretary, Authorized Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=2646035396","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646035396?lang=en_us&edition=fundamental","pubTime":"2026-06-26 17:26","pubTimestamp":1782466014,"startTime":"0","endTime":"0","summary":"WuXi XDC appoints Yuan Fang joint company secretary, authorized representativeWuXi XDC named Yuan Fang joint company secretary, effective June 26, 2026; she also becomes an authorized representative.F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL6Y0xcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0456827905.SGD","BK1574","LU3063872942.SGD","LU0348825331.USD","LU0417516902.SGD","LU1720050803.USD","LU0516422952.EUR","LU0516423174.USD","LU2488822045.USD","LU0140636845.USD","LU0516423091.SGD","IE00B0JY6N72.USD","LU1880383366.USD","LU1794554557.SGD","02137","BK1587","LU1688375341.USD","BK4139","BK1589","SG9999002463.SGD","LU0516422440.USD","LU0043850808.USD","BK1161","NBP","LU0516422366.SGD","LU0039217434.USD","LU0327786744.USD","LU1242518931.SGD","LU2039709279.SGD","BK1610","LU0348735423.USD","LU0051755006.USD","LU0456846285.SGD","BK1141","LU0359202008.SGD","02269","LU0052750758.USD","LU1242518857.USD","LU0588546209.SGD","02268","LU0823426480.USD","LU0708995583.HKD","LU0979878070.USD","LU0572944931.SGD","LU0417516738.SGD","BK1521","LU0819121731.USD","LU0307460666.USD","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178222691","title":"HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178222691","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178222691?lang=en_us&edition=fundamental","pubTime":"2026-06-23 09:56","pubTimestamp":1782179815,"startTime":"0","endTime":"0","summary":"Hong Kong-listed biotech stocks jumped on Tuesday. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up around 5%; Joinn, Remegen up about 4%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02268","02137","03759","06606","09966","06978","09606","01672","09995","02269","09688","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644747421","title":"Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644747421","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644747421?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:31","pubTimestamp":1781710267,"startTime":"0","endTime":"0","summary":"June 17 (Reuters) - Brii Biosciences Ltd <2137.HK>::*SHARE BUY-BACK PROGRAMME IS NO MORE THAN HK$60 MILLION*TO BUY BACK UP TO 10% OF ISSUED SHARES*Further company coverage: 2137.HK* ((Reuters.Briefs@t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nRSD6dM2RY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02137","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174175945","title":"BRII-B Announces Share Buyback Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=1174175945","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174175945?lang=en_us&edition=fundamental","pubTime":"2026-06-17 22:08","pubTimestamp":1781705307,"startTime":"0","endTime":"0","summary":"Biopharmaceutical firm BRII-B (ASX: 02137) has announced its intention to repurchase company shares.The board of directors intends to exercise its powers under the general mandate granted by...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.briibio.com","stockEarnings":[{"period":"1week","weight":0.0305},{"period":"1month","weight":0.015},{"period":"3month","weight":-0.1612},{"period":"6month","weight":-0.3494},{"period":"1year","weight":-0.5},{"period":"ytd","weight":-0.2801}],"compareEarnings":[{"period":"1week","weight":0.0355},{"period":"1month","weight":0.0449},{"period":"3month","weight":0.0158},{"period":"6month","weight":-0.0153},{"period":"1year","weight":0.036},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Brii Biosciences Ltd is a biotechnology company primarily engaged in the development of therapies for infectious diseases and central nervous system diseases. The Company's main products include BRII-179, a candidate drug for hepatitis B virus (HBV) immunotherapy, Tobevibart, an investigational neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg), as well as soralimixin (BRII-693), a synthetic lipopeptide for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacterial infections. The Company primarily operates its businesses in the domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.040695},{"month":2,"riseRate":0.6,"avgChangeRate":0.049398},{"month":3,"riseRate":0.2,"avgChangeRate":-0.163076},{"month":4,"riseRate":0.2,"avgChangeRate":-0.015797},{"month":5,"riseRate":0,"avgChangeRate":-0.081235},{"month":6,"riseRate":0.2,"avgChangeRate":-0.107834},{"month":7,"riseRate":0.8,"avgChangeRate":0.07356},{"month":8,"riseRate":0.333333,"avgChangeRate":0.016843},{"month":9,"riseRate":0.6,"avgChangeRate":-0.00155},{"month":10,"riseRate":0.2,"avgChangeRate":-0.127852},{"month":11,"riseRate":0.6,"avgChangeRate":0.286305},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154392}],"exchange":"SEHK","name":"BRII-B","nameEN":"BRII-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BRII-B(02137),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BRII-B(02137) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BRII-B,02137,BRII-B股票,BRII-B股票老虎,BRII-B股票老虎国际,BRII-B行情,BRII-B股票行情,BRII-B股价,BRII-B股市,BRII-B股票价格,BRII-B股票交易,BRII-B股票购买,BRII-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BRII-B(02137),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BRII-B(02137) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}